Abstract: An array substrate and a display panel are provided. The array substrate includes a base substrate, a plurality of data lines, and a plurality of color resists. A bending unit is provided on the data line, so that an edge of a portion where the color resist covers the bending unit does not overlap with the data line, and thus is conducive for an external device to monitor an actual width of the portion where the color resist covers the bending unit.

Abstract: The present disclosure introduces intranasal (IN) pharmaceutical formulations having naloxone or an opioid antagonist as the active agent, and an absorption enhancer, such as a bile acid, or a salt thereof, for IN delivery. The bile acid, or salt thereof, enhances absorption of naloxone or an opioid antagonist into the bloodstream of a human subject.

Abstract: Provided are a display device and a method for controlling the same. The display device includes: a display panel including a display module and a touch module, and having a first display area, a second display area and a first bending area located at a junction between the first display area andthe second display area, the display panel being bendable at the first bending area and a bendable circuit board having a second bending area, an orthographic projection of on the display panel overlaps the first bending area, the bendable circuit board is connected to a data driving unit and a touch driving unit, transmits a data signal of any of the first display area and the second display area to the data driving unit and transmits a touch signal of any of the first display area and the second display area to the touch driving unit.

Abstract: An apparatus for fixing a display includes a fixing frame and a positioning device. The fixing frame is defined by a plurality of surrounding side plates, a space for accommodating the display is surrounded by the side plates, and a cavity is formed within the side plate. The positioning device is provided within the cavity and includes a positioning assembly and a driving assembly. The positioning assembly includes an inserting-connecting member and a transmission mechanism, the inserting-connecting member is slidably extended into the space surrounded by the side plates, and the inserting-connecting member is connected to the transmission mechanism. The driving assembly is connected to the transmission mechanism and configured to drive, via the transmission mechanism, the inserting-connecting member to slide, so that the inserting-connecting member is inserted into or separated from an inserting hole in the display.

Abstract: Disclosed herein are pharmaceutical formulations including epinephrine that have increased epinephrine retention over long-term storage, e.g., 30-months. In one aspect, a formulation includes: one or more of 0.1 mg/mL of epinephrine or a pharmaceutically acceptable salt thereof provided without any overage, a tonicity regulating agent including 8.2 mg/mL of sodium chloride, a pH adjusting agent including a mixture of 1.5 mg/mL sodium citrate dihydrate, 3.3 mg/mL of citric acid monohydrate, and, optionally, an as-needed amount of sodium hydroxide to maintain the pH level of the formulation within a range of 3.6 to 4.0, 0.075 mg/mL of sodium metabisulfite, and 4 ?g/mL of ethylene diamine tetra-acetate disodium. The formulation has an API recovery of 94.5% or more after at least 30 months of storage at long-term storage conditions defined as 25° C.±2° C. at 1 atmosphere. In addition, in another aspect, a formulation includes 1 mg/mL of epinephrine and other ingredients.

Abstract: Disclosed herein are pharmaceutical formulations including epinephrine that have increased epinephrine retention over long-term storage, e.g., 30-months. In one aspect, a formulation includes: one or more of 0.1 mg/mL of epinephrine or a pharmaceutically acceptable salt thereof provided without any overage, a tonicity regulating agent including 8.2 mg/mL of sodium chloride, a pH adjusting agent including a mixture of 1.5 mg/mL sodium citrate dihydrate, 3.3 mg/mL of citric acid monohydrate, and, optionally, an as-needed amount of sodium hydroxide to maintain the pH level of the formulation within a range of 3.6 to 4.0, 0.075 mg/mL of sodium metabisulfite, and 4 ?g/mL of ethylene diamine tetra-acetate disodium. The formulation has an API recovery of 94.5% or more after at least 30 months of storage at long-term storage conditions defined as 25° C.±2° C. at 1 atmosphere. In addition, in another aspect, a formulation includes 1 mg/mL of epinephrine and other ingredients.

Abstract: The present disclosure provides NMR relaxation methods for characterizing iron carbohydrate drug products. The methods measure 13C and 1H nuclei relaxation parameters such as T1 and PWHH include performing 2D T1 NMR, 1D 13C NMR and 1H NMR to characterize certain physiochemical properties of iron sucrose drug products, for purposes of assessing bioequivalence between a tested iron sucrose product and a comparator product. The disclosure further provides a novel Fe(III)/Fe(II) reduction method using a new reducing agent Na2S2O5 and an 1H NMR method to monitor the Fe(III)/Fe(II) reduction process.

Abstract: The present disclosure introduces methods for characterizing iron core carbohydrate colloid drug products, such as iron sucrose drug products. Disclosed methods enable the characterization of the iron core size of the iron core nanoparticles in iron carbohydrates as they exist in the formulation in solution, such as e.g. iron sucrose drug products, and more particularly, the average particle diameter size and size distribution(s) of the iron core nanoparticles. The disclosed methods apply small-angle X-ray scattering (SAXS) in parallel beam transmission geometry, with a sample mounted inside a capillary and centered in the X-ray beam, to iron carbohydrates, such as iron sucrose, in solution without the need to modify the sample, such as to remove unbound carbohydrates, dilute, or dry the sample, to accurately characterize the average iron core particle diameter size of the iron core nanoparticles.

Abstract: Disclosed herein are use of IL-33 protein for the treatment, prevention, or reduction of onset or metastasis of a cancer by administering to a subject in need a therapeutically effective amount of IL-33 protein, such as human IL-33 protein, pharmaceutical compositions comprising IL-33 protein for treating cancer, and use of an agent capable of upregulating CD40/CD40L signaling pathway for treating cancer.

Abstract: Methods and systems provide spatialized locations and groupings of chat participants within a messaging platform. First, the system displays, for each of a number of participants within a messaging session, a spatial chat user interface consisting of a virtual background and one or more spatialized avatars, each being a representation of one of the participants overlaid on the virtual background, positioned in a spatialized location of the virtual background according to one or more location criteria, and one or more of the spatialized avatars positioned in a grouping according to one or more grouping criteria, where grouped spatialized avatars are positioned closer together than ungrouped spatialized avatars.

Abstract: Methods and systems provide for a spatial chat view within a messaging platform. First, the system displays, for a number of participants within a messaging session, a user interface consisting of: a virtual background; one or more spatialized avatars representing the participants overlaid on the virtual background; and a message composing component. The system displays, adjacent to each of a subset of the spatialized avatars, one or more chat bubbles corresponding to messages sent by one or more of the participants represented by the subset of the spatialized avatars. Concurrently or subsequently, the system determines an availability status for each of the plurality of participants, and then displays, within or adjacent to each of the spatialized avatars, a visual indicator of the availability status of the participant represented by the spatialized avatar.

Abstract: Methods and systems provide for a spatialized display of chat messages within a messaging platform. First, the system displays, for each of a number of participants within a messaging session, a spatial chat user interface (hereinafter “UI”) consisting of: a virtual background; and one or more spatialized avatars representing the participants. The system receives initial chat messages sent by a participant from the plurality of participants, then displays, adjacent to each of a subset of the spatialized avatars, one or more initial chat bubbles corresponding to messages sent by one or more of the participants represented by the subset of the spatialized avatars. Concurrently or subsequently, the system displays one or more other participant chat bubbles. The system receives additional chat messages sent by the participant, and then displays the additional chat bubbles, repositioning the initial chat bubbles while the additional chat bubbles are displayed in their place.

Abstract: Methods and systems provide dynamic background selection in a chat interface. First, the system receives metadata about a chat session comprising a number of participants. The system then determines a virtual background based on one or more background selection criteria and at least a subset of the metadata about the chat session. Finally, the system displays, for each of the participants in the chat session, a spatial chat user interface including the determined virtual background, with the one or more spatialized avatars overlaid on the virtual background and positioned spatially within it.

Abstract: Methods and systems provide for a spatial chat view dashboard within a messaging platform. A system displays, at a client device, a dashboard user interface for a messaging platform, consisting of at least a dashboard virtual background and one or more spatial chat rooms. Each of the spatial chat rooms is a spatial representation of a chat session associated with a number of participants. The system receives, from the client device, a selection of a spatial chat room from the one or more spatial chat rooms. The system then displays a spatial chat user interface comprising the selected spatial chat room.

Abstract: Disclosed herein are pharmaceutical formulations including epinephrine that have increased epinephrine retention over long-term storage, e.g., 30-months. In one aspect, a formulation includes: one or more of 0.1 mg/mL of epinephrine or a pharmaceutically acceptable salt thereof provided without any overage, a tonicity regulating agent including 8.2 mg/mL of sodium chloride, a pH adjusting agent including a mixture of 1.5 mg/mL sodium citrate dihydrate, 3.3 mg/mL of citric acid monohydrate, and, optionally, an as-needed amount of sodium hydroxide to maintain the pH level of the formulation within a range of 3.6 to 4.0, 0.075 mg/mL of sodium metabisulfite, and 4 ?g/mL of ethylene diamine tetra-acetate disodium. The formulation has an API recovery of 94.5% or more after at least 30 months of storage at long-term storage conditions defined as 25° C.±2° C. at 1 atmosphere. In addition, in another aspect, a formulation includes 1 mg/mL of epinephrine and other ingredients.

Abstract: An array substrate and a display panel are provided. The array substrate includes a base substrate, a plurality of data lines, and a plurality of color resists. A bending unit is provided on the data line, so that an edge of a portion where the color resist covers the bending unit does not overlap with the data line, and thus is conducive for an external device to monitor an actual width of the portion where the color resist covers the bending unit.

Abstract: A semiconductor device, a back-side deep trench isolation (BDTI) structure of a semiconductor device, and method of manufacturing a semiconductor structure are provided. The semiconductor device, comprising: a pixel region disposed within a substrate and comprising an image sensing element configured to convert electromagnetic radiation into an electrical signal; and one or more BDTI structures extending from a first-side of the substrate to positions within the substrate; wherein the one or more of BDTI structures comprise one or more ferroelectric materials.

Abstract: Methods, systems, electronic devices, and computer-readable storage media for image normalization processing are provided. In one aspect, an image normalization processing method includes: normalizing a feature map by respectively using K normalization factors to obtain K candidate normalized feature maps; for each of the K normalization factors, determining a first weight value for the normalization factor; and determining a target normalized feature map corresponding to the feature map based on the candidate normalized feature map corresponding to each of the K normalization factors and the first weight value for each of the K normalization factors. The K candidate normalized feature maps and the K normalization factors have a one-to-one correspondence, and K is an integer greater than 1.

Abstract: Methods are disclosed for producing highly purified recombinant human insulin (RHI) having a purity of 99.0% (w/w) or greater, a Total Impurity (not including the related substance desamido AsnA21-RHI, as specified by USP) of 0.8% (w/w) or less, and an impurity C of 0.1% (w/w) or less. Also disclosed are API compositions of highly purified RHI having a purity of 99.0% (w/w) or greater, a Total Impurity of 0.8% (w/w) or less, and an impurity C of 0.1% (w/w) or less.

Abstract: The present disclosure relates to a network training method, an electronic device and a storage medium. The network training method includes the following steps. At least one implicit vector may be input into at least one pre-trained generative network to obtain a first generated image; the generative network may be obtained with a discriminative network through adversarial trainings with a plurality of natural images. A degradation process may be performed on the first generated image to obtain a first degraded image of the first generated image. The implicit vector and the generative network may be trained according to the first degraded image and a second degraded image of at least one target image; the trained generative network and the trained implicit vector may be used to generate at least one reconstructed image of the target image.